Blueprint Medicines Corporation (BPMC) News
Filter BPMC News Items
BPMC News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
BPMC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BPMC News From Around the Web
Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued GrowthBlueprint Medicines Corporation (Nasdaq: BPMC) today provided a 2025 corporate outlook and strategy for continued growth leveraging the company's proven R&D and commercial capabilities. |
High Growth Tech Stocks to Watch in January 2025Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 24%, with earnings expected to grow by 15% per annum in the coming years. In this context of robust market performance and anticipated growth, identifying high growth tech stocks involves looking for companies with innovative solutions and strong potential to capitalize on emerging trends. |
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBlueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET). |
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingBlueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes. The datasets, which include one oral presentation and three poster presentations, will be reported |
Exploring Three High Growth Tech Stocks in the United StatesOver the last 7 days, the United States market has remained flat, yet it is up 32% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and scalability in a rapidly evolving sector. |
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': AnalystJP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune mast cells. In 2023, the FDA approved Blueprint Medicines’ Ayvakit (avapritinib) as the first, only treatment for indolent systemic mastocytosis (ISM). In the third quarter of 2024, Ayvakit reported net product revenues of $128.2 million, including $113.1 million in the U.S. and $15.1 million ex-U.S., representing 136% growth year over year. Blueprint Medicines anticipate |
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter ReportIt's been a good week for Blueprint Medicines Corporation ( NASDAQ:BPMC ) shareholders, because the company has just... |
High Growth Tech Stocks to Watch in November 2024Over the last 7 days, the United States market has dropped 1.6%, but over the longer term, it has risen by 30% in the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential for sustained revenue expansion in alignment with these market trends. |
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats ExpectationsBlueprint Medicines ( NASDAQ:BPMC ) Third Quarter 2024 Results Key Financial Results Revenue: US$128.2m (up 127% from... |